GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors.
about
Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndromeThe Pathogenesis of Resection-Associated Intestinal AdaptationInterdependency of EGF and GLP-2 Signaling in Attenuating Mucosal Atrophy in a Mouse Model of Parenteral NutritionGut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation.Proglucagon-derived peptides: mechanisms of action and therapeutic potential.Animal models of gastrointestinal and liver diseases. Animal models of infant short bowel syndrome: translational relevance and challenges.IGF binding protein-4 is required for the growth effects of glucagon-like peptide-2 in murine intestineEmerging treatment options for short bowel syndrome: potential role of teduglutideAxon-like basal processes in enteroendocrine cells: characteristics and potential targetsIncreased gut hormones and insulin sensitivity index following a 3-d intervention with a barley kernel-based product: a randomised cross-over study in healthy middle-aged subjects.Glucagon-like peptide-2-stimulated protein synthesis through the PI 3-kinase-dependent Akt-mTOR signaling pathway.Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in miceMechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblastsIrinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.Intestinal mucosal atrophy and adaptationDisruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritisGlucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells.Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion.Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats.Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle functionGlucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro.Glucagon-like peptide-2 (GLP-2) increases net amino acid utilization by the portal-drained viscera of ruminating calves.Growth factors: possible roles for clinical management of the short bowel syndrome.The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease.The "cryptic" mechanism of action of glucagon-like peptide-2.Treatment of adult short bowel syndrome patients with teduglutide.Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis.Review article: a comparison of glucagon-like peptides 1 and 2.The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis.Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.On the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome.Effect of porcine glucagon-like peptides-2 on tight junction in GLP-2R + IPEC-J2 cell through the PI3 k/Akt/mTOR/p70S6K signalling pathway.Teduglutide for treatment of adult patients with short bowel syndrome.Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats.Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity.Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine.Glucagon-like peptide 2 counteracts the mucosal damage and the neuropathy induced by chronic treatment with cisplatin in the mouse gastric fundus.The endogenous preproglucagon system is not essential for gut growth homeostasis in miceEffects of exogenous glucagon-like peptide-2 and distal bowel resection on intestinal and systemic adaptive responses in rats
P2860
Q24629712-AE71B710-A459-4C13-AAE5-A4695DBC7F3BQ28076127-1827BE63-9468-4434-9063-3E9BF42F5F2EQ33600424-21AA6421-C5DC-45C9-8A6F-32F1C48A2E86Q33865971-C975831E-D1FB-4F87-84E0-0989F5BA84F3Q34409674-241604FB-6B6F-40E9-AE32-527949BA8CD8Q34452524-8A69C154-4843-4A9B-8130-B54DAED6384FQ34726758-73BA6B06-D5D6-4C59-9B5C-BEDD41DC86BAQ34982361-E078D2F4-CC63-4A9A-8BD3-DC084E8C699AQ35304614-6BB63C17-399B-47ED-999B-D93560EC2F04Q35491959-A52C2621-E864-4D15-B309-AA78B6891462Q35741712-A68A3490-854D-44CA-964D-1A62D6F927CEQ35756432-6EB15F56-15DF-4137-A87C-5C89B46D51DEQ35986076-0C679B2D-DF84-47BF-A894-CE691A2049C9Q36063090-FE307F2C-B465-49E8-A1C9-F054C7FCD043Q36171894-4002C6D5-87A9-40A8-AB06-DF40ACA0F76FQ36429803-68FFD91C-6346-4FA8-B4D3-0A6302AE534DQ36710034-2ADDC2D9-41A5-4144-A7F6-37360B7B7F1AQ36710038-34E642E9-3648-4A00-899F-DFCDFA2436CBQ37138788-70CB0745-A294-46AC-83F1-1CA9CB734468Q37200132-8D51BCA7-AB92-41F7-B62D-F999A851B3D5Q37311786-70383748-40A2-4F8A-96B7-53A792ACDDEFQ37391813-39E6A540-5F46-495C-9486-ACC43036AAB8Q37681059-6CF1B533-3752-477D-9E08-1AC1117B5A73Q37685500-852C4C1A-EAEC-4A68-A802-631AFA7B6574Q37840099-099C2158-6EAA-4C75-A7D4-5B06A6D9C604Q37870031-B28F3577-CBC3-4EF2-9A3C-12E82B85E3DBQ37973750-071EEAE7-0360-4046-A961-36F5CB2F1ECDQ38048602-C367BF00-C3DC-4D7F-8C20-9FC788440A00Q38057350-42B91D77-F3BD-48A3-A575-1A73A319B352Q38101129-30C35D6A-0712-4263-B1EC-0E25135E33E5Q38107546-0D666C22-688C-4B84-A72F-BF8A049959D4Q38711705-808D4E94-FB24-4D64-A218-00CB0979F589Q38718059-72B959B5-7603-409F-88AB-BFBBBE1F2D14Q39178858-F7D0B72D-A733-4B7B-9614-2A1B68D9CC3AQ39974508-758A896A-A362-47DB-B2A0-6D67BC9E039FQ40074896-98A61E97-81CB-421D-AD21-ECDA7D99A600Q40116671-B889D867-AB93-4AC6-91E7-25CE0F219C74Q40345569-F074F6C8-61D0-49A1-946C-B0CCD85DD15EQ41038731-3FB45BE1-6323-463A-95C3-A86BC064C7E5Q41106209-D8D77C44-30C4-4F60-9027-18431FC21591
P2860
GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
GLP-2 stimulates colonic growt ...... roblasts with GLP-2 receptors.
@ast
GLP-2 stimulates colonic growt ...... roblasts with GLP-2 receptors.
@en
GLP-2 stimulates colonic growt ...... roblasts with GLP-2 receptors.
@nl
type
label
GLP-2 stimulates colonic growt ...... roblasts with GLP-2 receptors.
@ast
GLP-2 stimulates colonic growt ...... roblasts with GLP-2 receptors.
@en
GLP-2 stimulates colonic growt ...... roblasts with GLP-2 receptors.
@nl
prefLabel
GLP-2 stimulates colonic growt ...... roblasts with GLP-2 receptors.
@ast
GLP-2 stimulates colonic growt ...... roblasts with GLP-2 receptors.
@en
GLP-2 stimulates colonic growt ...... roblasts with GLP-2 receptors.
@nl
P50
P1433
P1476
GLP-2 stimulates colonic growt ...... roblasts with GLP-2 receptors.
@en
P2093
Jesper Thulesen
Kristine Juul Hare
P304
P356
10.1016/J.REGPEP.2004.07.009
P577
2005-01-01T00:00:00Z